“Lindys Health’s involvement in this study underpins our commitment to helping our partners bring safe and effective dermatological therapies to market. Inflammatory acne can significantly diminish quality of life,” states Michael Young, co-founder of Lindus Health. “We are enthusiastic about the opportunity to leverage our unique technical and service-based capabilities in another dermatology study, building on our vast experience in this space.”
"This study highlights the core underlying mechanism of action of our ovarian support cells in maturing eggs outside of the body and provides a deeper look into the role that Fertilo plays in promoting high quality egg maturation for IVF treatment," said Dr. Christian Kramme, Chief Scientific Officer of Gameto.
“Lindys Health’s involvement in this study underpins our commitment to helping our partners bring safe and effective dermatological therapies to market. Inflammatory acne can significantly diminish quality of life,” states Michael Young, co-founder of Lindus Health. “We are enthusiastic about the opportunity to leverage our unique technical and service-based capabilities in another dermatology study, building on our vast experience in this space.”
“This registry aims to provide interventional pain physicians in the United States with clinical data that supports the safety and effectiveness of the SiLO sacroiliac fixation technique. I am excited to be part of the study and to train others so that we can continue to advance therapies that relieve pain and restore function,” said Jack Diep, M.D., a Pain Medicine Specialist in Lake Havasu City, AZ.
In a published study, a team from Lawson Health Research Institute (LHSC), in Ontario Canada, has found that a simple medical device can reduce swelling after kidney transplantation.
LIBERTY 360° represents the largest, contemporary real-world experience with various endovascular strategies across the full range of Rutherford Class (RC) patients, including those with critical limb ischemia, the most compromised RC6 patients.
EXPAND is a prospective, randomized, single-blind, intra-patient controlled, post-market clinical trial enrolling approximately 80 patients in the United States.
The TITAN 1 Feasibility Study is a prospective, multicenter, feasibility study to characterize the procedure for the implantable TNM device in subjects with bladder incontinence.
By using this website you agree to accept Medical Device News Magazine Privacy Policy
